AptaBio Therapeutics Inc. (KOSDAQ:293780)

Market Cap	192.47B
Revenue (ttm)	3.36B
Net Income (ttm)	-29.38B
Shares Out	26.88M
EPS (ttm)	-1,247.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,152
Average Volume	53,130
Open	7,750.00
Previous Close	7,160.00
Day's Range	7,100.00 - 7,750.00
52-Week Range	4,930.00 - 15,490.00
Beta	1.62
RSI	47.05
Earnings Date	Apr 30, 2025

About AptaBio Therapeutics

AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical nee...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2009
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 293780

Financial Performance

In 2024, AptaBio Therapeutics's revenue was 3.36 billion, an increase of 937.76% compared to the previous year's 323.87 million. Losses were -29.38 billion, 147.6% more than in 2023.